abstract |
The present invention relates to GPR119 receptor agonists: 3-fluoro-4- (5-fluoro-6- (4- (3- (2-fluoropropan-2-yl) -1, 2, 4-oxadiazol-5- iI) piperidin-1-yl) pyrimidin-4-ylamino) -N, N-dimethylbenzamide; -fluoro-4- (5-fluoro-6- (4- (3- (2-fluoropropan-2- iI) -1, 2, 4-oxadiazol-5-yl) piperidin-1-yl) pyrimidin-4- ylamino) -Nm ethylbenzamide; and 3-fluoro-4- (5-fluoro-6- (4- (3- (2-fluoropropan-2-yl) -1, 2, 4-oxadiazol-5-iI) piperidin-1-yl) pyrimidin- 4-ylamino) benzam ida, and pharmaceutically acceptable salts, solvates and hydrates thereof, which are useful as an individual pharmaceutical agent or in combination with one or more additional pharmaceutical agents, such as, a DPP-IV inhibitor, a biguanide , an alga-glucosidase inhibitor, an insulin analog, a sulfonylurea, an SGLT2 inhibitor, a meglitinide, a thiazolidinedione, or an anti-diabetic peptide analog, in the treatment of, for example, a disorder selected from: a disorder related to the GPR119 receptor; a condition enhanced by the increase in secretion of an incretin; a condition enhanced by the increase in a blood incretin level; a condition characterized by a low bone mass; a neurological disorder; a metabolic related disorder; type 2 diabetes; obesity; and related complications. |